Why Ferrari Shares Are High On Racing Today

Ferrari NV (NYSE:RACE) reported first-quarter FY23 sales growth of 20.5% year-on-year to €1.42 billion. Total shipments of 3,567 units improved 9.7% from…
  • Ferrari NV (NYSE:RACE) reported first-quarter FY23 sales growth of 20.5% year-on-year to €1.42 billion. Total shipments of 3,567 units improved 9.7% from last year.
  • Car and spare parts revenue rose 23% Y/Y, and Engines decreased by 12%.
  • Adjusted EBITDA rose 27% Y/Y to €537 million, and the margin expanded 200 basis points Y/Y to 37.6%.
  • Net profit for the quarter increased 24% to €297 million.
  • Adjusted EPS of €1.62 rose 26% from €1.29 last year.
  • Cash flow from operating activities totaled €398 million with a €248 million free cash flow.
  • Benedetto Vigna, Ferrari CEO, said, “Our order book already extends into 2025 with an award-winning product portfolio. We have decided to reopen orders for the Purosangue, suspended due to an initial unprecedented demand, and launched the Roma Spider to further enrich our offer. We are on track with our electrification journey on the development of both sports cars and infrastructures in Maranello.”
  • Also Read: Ferrari Teams Up with Samsung for High-Tech In-Car Displays
  • Price Action: RACE shares are trading higher by 4.87% at $291.15 on the last check Thursday.
  • Photo Via Company
Total
0
Shares
Related Posts
Read More

Oncolytics Biotech’s Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating The Anti-Cancer Activity Of Pelareorep-Paclitaxel Combination Therapy In HR+/HER2- Metastatic Breast Cancer At SABCS

Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage SAN DIEGO and CALGARY, AB, Dec. 8, 2022 /CNW/ -- Oncolytics

ONCY

Read More

Reported Late Tuesday, Eisai And Biogen Present Full Results Of Lecanemab Phase 3 Confirmatory Clarity AD Study For Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease Conference: Primary And Key Secondary Endpoints Were Changed From Ba…

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: , Cambridge, Massachusetts, CEO: , Christopher A.

BIIB